Skip to main content

Genetically engineered human pluripotent stem cells, functionalized silk-fibroin platforms and bio-inks: a novel solution for large-scale ex-vivo platelet production, transfusion and drug research

Objective

"The demand for human platelets (plts) for medical research and clinical applications is massive. The primary goal of SilkFUSION is to engineer groundbreaking 3D nanotechnologies for large-scale production of blood plts for human transfusion from human pluripotent stem cells (hPSCs). Our hypothesis is that plt production ex-vivo can be optimized by providing megakaryocytes (Mks) with the correct physical and biochemical environment.

To prove this, we will develop a unique technological platform by engineering non-thrombogenic silk-fibroin biomaterial with proteins, that were proven to promote a 55-fold gain in plt production, to create a three-dimensional ex-vivo bone marrow model that will enhance plt release from Mks derived from hPSCs. Our platform will include (i) novel applications to study pathogenetic mechanisms in patients with inherited platelet production disorders using genetically modified hPSCs; (ii) screening technology for predicting therapeutic efficacy of drugs for thrombocytopenic patients. The development of this technology will exploit an extremely innovative approach using silk-fibroin as a bio-ink for 3D printing a ""live chip"" containing viable Mks for reproducible drug testing.

Our long-term vision is to foster the production of plts in-vitro for clinical transfusions in humans at a scale and cost that will address current supply challenges regarding (i) immunologically matched products to alloimmunised patients; (ii) “supercharged” platelets with recombinant FVIIa generating plts specifically suited for patients with acute haemorrhage resulting from trauma, surgery and wounded in conflict zones. The successful development and distribution of the SilkFUSION platforms will also offer researchers and clinicians specialized precision instruments and bio-ink kits for determining the safety and efficacy of drugs, reducing costs of ineffective therapies while promoting affordable functional strategies for the development of novel molecules."

Field of science

  • /medical and health sciences/clinical medicine/surgery
  • /medical and health sciences/medical biotechnology/cells technologies/stem cells
  • /engineering and technology/nanotechnology
  • /natural sciences/biological sciences/biochemistry/biomolecules/proteins

Call for proposal

H2020-FETOPEN-1-2016-2017
See other projects for this call

Funding Scheme

RIA - Research and Innovation action

Coordinator

UNIVERSITA DEGLI STUDI DI PAVIA
Address
Strada Nuova 65
27100 Pavia
Italy
Activity type
Higher or Secondary Education Establishments
EU contribution
€ 738 327,49

Participants (5)

THE CHANCELLOR MASTERS AND SCHOLARSOF THE UNIVERSITY OF CAMBRIDGE
United Kingdom
EU contribution
€ 688 327,50
Address
Trinity Lane The Old Schools
CB2 1TN Cambridge
Activity type
Higher or Secondary Education Establishments
INSTITUT GUSTAVE ROUSSY
France
EU contribution
€ 688 327,50
Address
Rue Camille Desmoulins 39
94805 Villejuif
Activity type
Research Organisations
INTEGRATED SYSTEMS ENGINEERING SRL
Italy
EU contribution
€ 319 580,63
Address
Via Volturno Cedri 80
20816 Brugherio
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
CELLINK AB
Sweden
EU contribution
€ 344 163,75
Address
Arvid Wallgrens Backe 20
413 46 Goteborg
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
KNOWLEDGE INNOVATION MARKET S.L.
Spain
EU contribution
€ 219 773,13
Address
Calle Venezuela 103 Planta 1 Puerta
08019 Barcelona
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)